{"id":"pimecrolimus-cream-1","safety":{"commonSideEffects":[{"rate":"10-25","effect":"Application site burning or irritation"},{"rate":"1-5","effect":"Headache"},{"rate":"1-5","effect":"Nasopharyngitis"},{"rate":"1-5","effect":"Skin infections"},{"rate":"1-5","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pimecrolimus is a calcineurin inhibitor that selectively suppresses T-lymphocyte activation and prevents the release of inflammatory mediators such as TNF-α, IL-2, and IL-4. By blocking calcineurin-dependent signaling pathways, it reduces the proliferation and activation of immune cells involved in the inflammatory cascade of atopic dermatitis, leading to decreased skin inflammation and pruritus.","oneSentence":"Pimecrolimus inhibits T-cell activation and inflammatory cytokine release by binding to calcineurin, thereby reducing skin inflammation in atopic dermatitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:20.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (mild to moderate)"},{"name":"Atopic dermatitis in patients intolerant to or inadequate responders to conventional topical therapies"}]},"trialDetails":[{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT00568997","phase":"","title":"10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-06-27","conditions":"Atopic Dermatitis","enrollment":8000},{"nctId":"NCT02376049","phase":"PHASE1","title":"A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT06052995","phase":"","title":"Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.","status":"UNKNOWN","sponsor":"MEDA PHARMA SPA, a Viatris company","startDate":"2023-11","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":130},{"nctId":"NCT04976868","phase":"","title":"Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2021-03-18","conditions":"Atopic Dermatitis","enrollment":130},{"nctId":"NCT05729074","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-13","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":80},{"nctId":"NCT01082393","phase":"PHASE4","title":"Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-02-16","conditions":"Vitiligo","enrollment":14},{"nctId":"NCT00403559","phase":"PHASE2","title":"A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Dermatology Specialists Research","startDate":"2007-05-07","conditions":"Seborrheic Dermatitis","enrollment":113},{"nctId":"NCT03107611","phase":"PHASE3","title":"Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2016-02-29","conditions":"Atopic Dermatitis","enrollment":654},{"nctId":"NCT00120523","phase":"PHASE3","title":"5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2004-04","conditions":"Atopic Dermatitis","enrollment":2418},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT04900948","phase":"PHASE4","title":"Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life","status":"COMPLETED","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2017-12-10","conditions":"Atopic Dermatitis","enrollment":108},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT02791308","phase":"PHASE3","title":"Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":587},{"nctId":"NCT00128245","phase":"PHASE2","title":"Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Keratoconjunctivitis Sicca","enrollment":440},{"nctId":"NCT00208026","phase":"PHASE1, PHASE2","title":"Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2005-09","conditions":"Netherton Syndrome","enrollment":3},{"nctId":"NCT02896101","phase":"PHASE3","title":"Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2016-08","conditions":"Atopic Dermatitis","enrollment":755},{"nctId":"NCT03834935","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba","status":"UNKNOWN","sponsor":"St Joseph University, Beirut, Lebanon","startDate":"2019-03-01","conditions":"Pityriasis Alba","enrollment":40},{"nctId":"NCT00222183","phase":"NA","title":"Cutaneous Lupus Erythematosus and Elidel","status":"WITHDRAWN","sponsor":"University of Leipzig","startDate":"2003-06","conditions":"Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid","enrollment":""},{"nctId":"NCT00509990","phase":"PHASE4","title":"Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-04","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT03297502","phase":"PHASE3","title":"Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2016-06","conditions":"Atopic Dermatitis","enrollment":582},{"nctId":"NCT01692626","phase":"PHASE2","title":"1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-02","conditions":"Rash","enrollment":13},{"nctId":"NCT00367393","phase":"PHASE4","title":"Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Atopic Dermatitis","enrollment":41},{"nctId":"NCT00925730","phase":"PHASE4","title":"Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00510003","phase":"PHASE4","title":"Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-12","conditions":"Atopic Dermatitis","enrollment":117},{"nctId":"NCT02583022","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2013-06","conditions":"Atopic Dermatitis","enrollment":74},{"nctId":"NCT02443311","phase":"PHASE4","title":"Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2010-09","conditions":"Oral Lichen Planus","enrollment":24},{"nctId":"NCT00568412","phase":"PHASE4","title":"A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":80},{"nctId":"NCT00666159","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00666302","phase":"PHASE4","title":"A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-10","conditions":"Dermatitis, Atopic","enrollment":413},{"nctId":"NCT00667160","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":426},{"nctId":"NCT00610142","phase":"PHASE2","title":"Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2007-12","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00655512","phase":"PHASE1","title":"Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2008-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT00393263","phase":"PHASE2","title":"Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Center for Vulvovaginal Disorders","startDate":"2006-10","conditions":"Lichen Sclerosus","enrollment":38},{"nctId":"NCT00946478","phase":"NA","title":"Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-10","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT00322569","phase":"PHASE3","title":"A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)","status":"COMPLETED","sponsor":"Cordis US Corp.","startDate":"2006-07","conditions":"Coronary Disease","enrollment":246},{"nctId":"NCT00297037","phase":"PHASE2","title":"Pimecrolimus Cream for Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-08","conditions":"Oral Lichen Planus","enrollment":21},{"nctId":"NCT01524744","phase":"PHASE2","title":"A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2009-03","conditions":"Oral Lichen Planus","enrollment":40},{"nctId":"NCT01202149","phase":"PHASE4","title":"Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Frankel, Amylynne, M.D.","startDate":"2010-03","conditions":"Eczema, Atopic Dermatitis","enrollment":30},{"nctId":"NCT00124709","phase":"PHASE4","title":"Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-10","conditions":"Atopic Dermatitis","enrollment":1091},{"nctId":"NCT01177566","phase":"PHASE4","title":"Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.","status":"COMPLETED","sponsor":"Emer, Jason, M.D.","startDate":"2009-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00119158","phase":"PHASE4","title":"Combination Therapy for Atopic Dermatitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-10","conditions":"Atopic Dermatitis","enrollment":90},{"nctId":"NCT00507832","phase":"PHASE2","title":"Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2007-04","conditions":"Prurigo Nodularis","enrollment":30},{"nctId":"NCT01132079","phase":"NA","title":"Pimecrolimus and Epidermal Barrier Function","status":"COMPLETED","sponsor":"University of Kiel","startDate":"2005-03","conditions":"Atopic Dermatitis","enrollment":15},{"nctId":"NCT00810862","phase":"PHASE4","title":"Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children","status":"TERMINATED","sponsor":"Children's Hospital of Michigan","startDate":"2006-11","conditions":"Atopic Dermatitis","enrollment":18},{"nctId":"NCT00139581","phase":"PHASE4","title":"Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT00226707","phase":"PHASE3","title":"Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-07","conditions":"Chronic Hand Dermatitis","enrollment":652},{"nctId":"NCT00608673","phase":"NA","title":"Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-04","conditions":"Discoid Lupus Erythematosus","enrollment":10},{"nctId":"NCT00150059","phase":"PHASE4","title":"Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-12","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT00484003","phase":"PHASE4","title":"A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Atopic Eczema","enrollment":""},{"nctId":"NCT00460083","phase":"PHASE4","title":"Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Ceragenix Pharmaceuticals","startDate":"2007-04","conditions":"Atopic Dermatitis","enrollment":35},{"nctId":"NCT00232115","phase":"PHASE3","title":"Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-09","conditions":"Perioral Dermatitis","enrollment":124},{"nctId":"NCT00351052","phase":"PHASE3","title":"Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2001-12","conditions":"Atopic Dermatitis","enrollment":184},{"nctId":"NCT00120302","phase":"PHASE4","title":"Quality of Life Study in Adults With Facial Eczema","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-03","conditions":"Atopic Dermatitis","enrollment":76},{"nctId":"NCT00130364","phase":"PHASE4","title":"Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-08","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT00121381","phase":"PHASE4","title":"Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Dermatitis, Atopic","enrollment":400},{"nctId":"NCT00121316","phase":"PHASE4","title":"Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT00117377","phase":"PHASE4","title":"Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-04","conditions":"Atopic Dermatitis","enrollment":70},{"nctId":"NCT00231998","phase":"PHASE3","title":"Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-05","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT00232011","phase":"PHASE3","title":"Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-05","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT00321750","phase":"PHASE2","title":"Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2004-12","conditions":"Oral Erosive Lichen Planus","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":124,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Elidel","ASM981","elidel cream","Eczema","Elidel 1% cream"],"phase":"marketed","status":"active","brandName":"Pimecrolimus Cream 1%","genericName":"Pimecrolimus Cream 1%","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pimecrolimus inhibits T-cell activation and inflammatory cytokine release by binding to calcineurin, thereby reducing skin inflammation in atopic dermatitis. Used for Atopic dermatitis (mild to moderate), Atopic dermatitis in patients intolerant to or inadequate responders to conventional topical therapies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}